Durvalumab vs Tirzepatide

Durvalumab vs Tirzepatide: Overview

This comparison examines the pharmacological differences between Durvalumab and Tirzepatide.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Tirzepatide: Dual GIP and GLP-1 receptor agonist.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Tirzepatide — 5 days.

Chemical Properties

Type: Durvalumab — Antibody; Tirzepatide — Protein.